# Axitinib and Nivolumab for the Treatment of Mucosal Melanoma

> **NCT05384496** · PHASE2 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 20 (estimated)

## Conditions studied

- Mucosal Melanoma

## Interventions

- **DRUG:** Nivolumab and/or Ipilimumab
- **RADIATION:** Stereotactic Body Radiation Therapy (SBRT)
- **DRUG:** axitinib

## Key facts

- **NCT ID:** NCT05384496
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-17
- **Primary completion:** 2027-05
- **Final completion:** 2027-05
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-02-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05384496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05384496, "Axitinib and Nivolumab for the Treatment of Mucosal Melanoma". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT05384496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*